Venetoclax

Overview

ABT-199 is an anti-apoptotic protein Bcl-2 inhibitor that mimics BH3-only proteins, the native ligands of Bcl-2 and programmed cell death activators, repressing Bcl-2 activity and restoring apoptotic processes in tumor cells.

SparkCures ID 24
Developed By AbbVie
Generic Name Venetoclax
Additional Names ABT-199
Treatment Classifications

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Phase III BELLINI: Updated Results With Venetoclax or Placebo Plus Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

May 31, 2020

  • Venetoclax added to Vd significantly improved PFS, ORR, and MRD negative rates in patients with R/R multiple myeloma but was associated with worse OS outcomes
  • Increased incidence of deaths attributed to infections
  • (11;14) cytogenetic marker associated with favorable risk-benefit profile for survival outcomes with venetoclax + Vd combination
  • Investigators conclude that the results support a t(11;14) biomarker-driven approach for venetoclax development in R/R multiple myeloma

Resources

Genetech Patient Foundation

Living with a serious illness can come with many challenges. Getting Genentech medicines shouldn’t be one of them.

The Genentech Patient Foundation gives free Genentech medicine to people who don’t have insurance coverage or who have financial concerns.